Weekly docetaxel monotherapy for metastatic extramammary Paget's disease: Retrospective single-institute analysis.
Aged
Aged, 80 and over
Antineoplastic Agents
/ administration & dosage
Docetaxel
/ administration & dosage
Dose-Response Relationship, Drug
Drug Administration Schedule
Feasibility Studies
Female
Humans
Male
Middle Aged
Paget Disease, Extramammary
/ drug therapy
Progression-Free Survival
Retrospective Studies
Skin Neoplasms
/ drug therapy
chemotherapy
docetaxel
extramammary Paget’s disease
metastatic
weekly
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
02
12
2019
accepted:
08
01
2020
pubmed:
6
2
2020
medline:
7
1
2021
entrez:
6
2
2020
Statut:
ppublish
Résumé
Monthly docetaxel (DTX) monotherapy is the first-line regimen that is preferably used for metastatic extramammary Paget's disease (EMPD). However, the high-dose DTX regimen frequently causes severe hematological adverse events (AE). To overcome such safety concerns, a weekly low-dose DTX monotherapy has been proposed for use in the treatment of various cancer types. In this study, we aimed to evaluate the feasibility and efficacy of weekly DTX (25 mg/m
Identifiants
pubmed: 32020662
doi: 10.1111/1346-8138.15255
doi:
Substances chimiques
Antineoplastic Agents
0
Docetaxel
15H5577CQD
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
418-422Subventions
Organisme : AMED
ID : JP17lk0201063
Informations de copyright
© 2020 Japanese Dermatological Association.
Références
Wang Z, Lu M, Dong GQ et al. Penile and scrotal Paget’s disease: 130 Chinese patients with long-term follow-up. BJU Int 2008; 102: 485-488.
Ohara K, Fujisawa Y, Yoshino K et al. Proposal for a TNM staging system for extramammary Paget disease: retrospective analysis of 301 patients with invasive primary tumors. J Dermatol Sci 2016; 83: 234-239.
Hatta N, Yamada M, Hirano T, Fujimoto A, Morita R. Extramammary Paget’s disease: treatment, prognostic factors and outcome in 76 patients. Br J Dermatol 2008; 158: 313-318.
Tokuda Y, Arakura F, Uhara H. Combination chemotherapy of low-dose 5-fluorouracil and cisplatin for advanced extramammary Paget’s disease. Int J Clin Oncol 2015; 20: 194-197.
Oashi K, Tsutsumida A, Namikawa K et al. Combination chemotherapy for metastatic extramammary Paget disease. Br J Dermatol 2014; 170: 1354-1357.
Matsushita S, Yonekura K, Mera K et al. Successful treatment of metastatic extramammary Paget’s disease with S-1 and docetaxel combination chemotherapy. J Dermatol 2011; 38: 996-998.
Hirai I, Tanese K, Nakamura Y et al. Combination cisplatin-epirubicin-paclitaxel therapy for metastatic extramammary Paget’s disease. Oncologist 2019; 24: e394-e396.
Yoshino K, Fujisawa Y, Kiyohara Y et al. Usefulness of docetaxel as first-line chemotherapy for metastatic extramammary. Pagets Dis J Dermatol 2016; 43: 633-637.
Kato M, Yoshino K, Maeda T et al. Single-agent taxane is useful in palliative chemotherapy for advanced extramammary Paget disease: a case series. Br J Dermatol 2019; 181(4): 831-832.
FDA.Drug Approval Package: Taxotere (Docetaxel) NDA #20449s028. Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/20-449s028_Taxotere.cfm
Baker SD, Zhao M, Lee CK et al. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res 2004; 10: 1976-1983.
Bruno R, Hille D, Riva A et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16: 187-196.
Schroder CP, de Munck L, Westermann AM et al. Weekly docetaxel in metastatic breast cancer patients: no superior benefits compared to three-weekly docetaxel. Eur J Cancer 2011; 47: 1355-1362.
Velluswamy RR, Levy B, Wisnivesky JP. Chemotherapy in elderly patients with nonsmall cell lung cancer. Curr Opin Pulm Med 2016; 22: 336-343.